alpha-aminopyridine has been researched along with Hematologic Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, H; Ebi, H; Fukushima, S; Hashimoto, N; Irie, K; Iwata, H; Kajita, M; Maeda, A; Okada, A; Sawaki, M | 1 |
| Agresta, SV; Attar, EC; Collins, R; de Botton, S; DiNardo, CD; Frattini, MG; Kantarjian, HM; MacBeth, KJ; Pollyea, DA; See, WL; Stein, AS; Stein, EM; Tallman, MS; Tosolini, A; Xu, Q | 1 |
| Cripe, LD; De Vos, S; Friedberg, JW; Gregory, SA; Johnston, PB; Lacasce, A; Leonard, JP; Levy, R; Lowe, AM; Schaefer-Cutillo, J; Sharman, J; Shipp, MA; Sinha, R; Sterba, MP; Sweetenham, J; Vose, JM | 1 |
2 trial(s) available for alpha-aminopyridine and Hematologic Diseases
| Article | Year |
|---|---|
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Aminopyridines; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutant Proteins; Mutation; Remission Induction; Treatment Outcome; Triazines | 2019 |
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Cohort Studies; Diarrhea; Disease-Free Survival; Female; Hematologic Diseases; Humans; Hypertension; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Morpholines; Neoplasm Proteins; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Salvage Therapy; Syk Kinase; Treatment Outcome | 2010 |
1 other study(ies) available for alpha-aminopyridine and Hematologic Diseases
| Article | Year |
|---|---|
Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Creatinine; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neutrophils; Patient Acuity; Platelet Count | 2021 |